Related Experiment Video
Updated: Mar 15, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy
Junli Deng1,2,3,4, Li Wang3,4, Jie Ni1,2
1a Cancer Care Centre , St George Hospital , Kogarah , Australia.
Introduction:
Chemoresistance is a major challenge to current ovarian cancer chemotherapy. It is important to identify biomarkers to distinguish chemosensitive and chemoresistant patients. Areas covered: We review the medical literature, discuss MS-based technologies with respect to chemoresistant ovarian cancer and summarize the promising chemoresistant biomarkers identified. In addition, the challenges and future perspectives of biomarker discovery research are explored. With the employment of mass spectrometry-based (MS-based) proteomics, biomarker discovery of ovarian cancer has made great progress in the last decade. Many potential biomarkers were identified by MS-based proteomics technologies, some of which have been validated for further extensive studies in clinical settings. Expert commentary: The discovery of chemoresistant biomarkers is a newly developing area and may provide a clue for predicting chemotherapeutic response and discover therapeutic targets for paving the way of personalized medicine. Multiple complementary MS-based proteomics approaches hold promise for finding novel therapeutic targets in ovarian cancer treatment.
Insights
Identifying chemoresistance biomarkers in ovarian cancer is crucial for personalized medicine. Mass spectrometry-based proteomics offers promising avenues for discovering these biomarkers to predict treatment response.
Area of Science:
- Oncology
- Biomarker Discovery
- Proteomics
Background:
- Chemoresistance presents a significant challenge in ovarian cancer treatment.
- Identifying reliable biomarkers is essential to differentiate between chemosensitive and chemoresistant patients.
Purpose of the Study:
- To review medical literature on chemoresistant ovarian cancer.
- To discuss mass spectrometry-based (MS-based) technologies for biomarker discovery.
- To summarize promising chemoresistance biomarkers and explore future research directions.
Main Methods:
- Literature review focusing on MS-based proteomics.
- Analysis of identified potential biomarkers for ovarian cancer chemoresistance.
- Discussion of challenges and future perspectives in biomarker discovery.
Main Results:
- MS-based proteomics has significantly advanced ovarian cancer biomarker discovery.
- Numerous potential biomarkers for chemoresistance have been identified.
- Some biomarkers have undergone validation for clinical studies.
Conclusions:
- Chemoresistance biomarker discovery is an emerging field with potential for predicting treatment outcomes.
- Biomarkers can guide the development of therapeutic targets for personalized ovarian cancer medicine.
- Complementary MS-based proteomics approaches show promise for identifying novel therapeutic targets.
More Related Videos
11:51Preparation of Mitochondria from Ovarian Cancer Tissues and Control Ovarian Tissues for Quantitative Proteomics Analysis
Published on: November 18, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
